<DOC>
	<DOCNO>NCT01378871</DOCNO>
	<brief_summary>This clinical trial multicenter phase II fixed-dose trial minimum 10 patient immunophenotypically confirm ATL least 50 % blast express CD25 measure flow cytometry relapse , receive Imtox-25 . Patients eligible repeat course treatment every two week experience dose limit toxicity ( DLT ) define Section 5.2 HAMA/HARA level &gt; 1 μg/ml . The treatment administer in-patient setting . If response observe among initial 9 patient , study would terminate early declare negative ; least one response observe , accrual would continue total 17 evaluable patient ( total study size=19 account 10 % patient unevaluable reason ) .</brief_summary>
	<brief_title>A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma</brief_title>
	<detailed_description>Adult T Cell Leukemia/Lymphoma ( ATL ) lymphoproliferative disease associate HTLV-1 infection , characterize circulate malignant cell express IL-2 receptor ( CD25 ) . Prognosis patient ATL remain poor despite advance chemotherapy , survival leukemic patient range six month less one year . Novel agent potent specific tumor cell urgently need improve overall survival decrease toxicity dismal disease . One therapeutic approach would use immunotoxins ( ITs ) . ITs utilize potent toxin link target moiety design maximize drug delivery tumor cell , thus avoid nonspecific toxicity conventional chemotherapeutic agent . Imtox-25 construct use RFT5 murine monoclonal antibody ( Mab ) couple deglycosylated ricin-A chain ( dgA ) via heterobifunctional , thiol-containing crosslinker , 4 [ ( succinimidyloxy ) carbonyl ] -ƒÑ-methyl-ƒÑ- ( 2 pyridyldithio ) toluene ( SMPT ) . Phase I II clinical study Imtox-25 ( RFT5.dGA ) show safety efficacy adult patient Hodgkin¡¦s disease recommend Phase II dose established.. In vitro experiment use ATL cell line vivo study murine xenograft model demonstrate significant activity Imtox-25 disease . Based result , investigator propose conduct phase II trial utilize Imtox-25 adult relapse refractory ATL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<criteria>Age &gt; 17 year inclusive time original diagnosis HTLV1 associate ATL . Histologic verification ATL HTLV1 seropositivity diagnosis either evidence relapse/refractory disease base Bone Marrow/Peripheral Blood examination evidence flow cytometry . Disease refractory conventional CHOP base therapy transplantation deem ineligible salvage transplantation . Presence CD25 least 50 % lymphoblast obtain via BMA peripheral blood determine flow cytometry . ECOG performance status 2 . Life expectancy &gt; 2 month . Patients must recover effect prior therapy . At least 2 week elapse since last dose chemotherapy ( 4 week case nitrosoureacontaining therapy ) . Steroids consider chemotherapy . However , patient recover side effect prior therapy &gt; 50 % rise peripheral blast count , immediately eligible . The 50 % rise peripheral blast count must calculate follow . The sample baseline peripheral blast count must take least 24 hour end chemotherapy . The sample peripheral blast count increase 50 % baseline peripheral blast count may take subsequent time . A second peripheral blast count confirm 50 % rise recommend . No hematopoietic limitation patient relapse leukemia routinely pancytopenia ITs demonstrated hematopoietic toxicity . Adequate renal function define serum creatinine 1.5 x normal range . Adequate liver function define total bilirubin 1.5 x normal range SGOT ( AST ) SGPT ( ALT ) 1.5 x normal range . Adequate cardiac function define shorten fraction 27 % echocardiogram , ejection fraction 3540 % MUGA scan . Adequate pulmonary function define evidence dyspnea rest . Normal neurological exam . Patient and/or legal guardian must sign write informed consent . All institutional , FDA , NCI requirement human study must meet . Presence leukemic infectious pulmonary parenchymal disease presence pulmonary effusion chest xray . Presence CNS involvement leukemia . History documented seizure disorder abnormal neurological examination . Human antimouse ( HAMA ) level &lt; 1 μg/ml .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>T Cell</keyword>
	<keyword>T-Cell</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia/Lymphoma</keyword>
	<keyword>ATL</keyword>
</DOC>